Who Buys Olaparib from India — 99 Importers Behind a $922.2K Market
India's olaparib import market is served by 99 active buyers who collectively imported $922.2K across 307 shipments. JSCRPH (RUSSIA) leads with a 27.2% market share, followed by LEK PHARMACEUTICALS D.D. and AS PER INVOICE AS. The top 5 buyers together control 53.8% of total import value, reflecting a moderately competitive buyer landscape.
Top Olaparib Importers — Ranked by Import Value
JSCRPH (RUSSIA) is the leading olaparib importer from India, holding a 27.2% share of the $922.2K market across 307 shipments from 99 buyers. The top 5 buyers — JSCRPH (RUSSIA), LEK PHARMACEUTICALS D.D. (SLOVENIA), AS PER INVOICE AS (SWITZERLAND), AS PER INVOICE ASPER INVOICE (BAHAMAS), TO THE IMPORT MANAGER (UNITED ARAB EMIRATES) — collectively control 53.8% of total import value.
Top Olaparib Buyers & Importers
Ranked by import value · 99 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | JSCRPHRUSSIA PHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 150 MG (OPHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 100 MG (OOLAPARIB TABLETS 150 MG | $251.3K | 5 | 27.2% |
| 2 | LEK PHARMACEUTICALS D.D.SLOVENIA OLAPARIB FCT 150MG B/N: 32377858 (120 TAOLAPARIB FCT 100MG B/N: 32380402 (120 TAOLAPARIB FCT 150MG B/N: 32378842 (120 TA | $159.9K | 5 | 17.3% |
| 3 | AS PER INVOICE ASSWITZERLAND HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USETABOLASP 150 OLAPARIB 150MG (HARMLESS MEDICINE FOR HUMAN CONSUMPTIONTABS. OLAPARIB 150MG | $33.9K | 5 | 3.7% |
| 4 | AS PER INVOICE ASPER INVOICEBAHAMAS HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USETABOLASP 150 OLAPARIB 150MG (HARMLESS MEDICINE FOR HUMAN CONSUMPTIONTABS. OLAPARIB 150MG | $29.5K | 5 | 3.2% |
| 5 | TO THE IMPORT MANAGERUNITED ARAB EMIRATES PHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 150 MG (OHARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USEPHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 100 MG (O | $21.6K | 5 | 2.3% |
| 6 | LS MEDISUR SACPERU OLAZYN 150 OLAPARIB TABLETS 150 MGOLAPARIB FCT 150MG B/N: 32377858 (120 TAOLAZYN 150 PHARMACEUTICAL FORMULATIONS | $16.9K | 5 | 1.8% |
| 7 | AS PER INVOICESWITZERLAND HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USETABOLASP 150 OLAPARIB 150MG (HARMLESS MEDICINE FOR HUMAN CONSUMPTIONTABS. OLAPARIB 150MG | $15.6K | 5 | 1.7% |
| 8 | `TO THE ORDER OFLITHUANIA HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE | $14.8K | 5 | 1.6% |
| 9 | PROGRESSIVE PHARMACEUTICAL DISTRIBUBAHAMAS OLAPARIB 150 MG NATCO BRAND BRACNAT | $13.9K | 5 | 1.5% |
| 10 | NAME:- VARGA ROSA PINHEIROBRAZIL HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE | $13.1K | 5 | 1.4% |
| 11 | SOVIPMEDISMOZAMBIQUE OLAPARIB FILM COATED TABLETS 150MG IYNPA | $11.1K | 5 | 1.2% |
| 12 | TO THE EXP CODE E0187FARMACIA INTERNAZIONALE BORDONI SASWITZERLAND PHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 150 MG (OHARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USEPHARMACEUTICAL MATERAIL - OLAPARIBTABLETS 100 MG (O | $9.8K | 5 | 1.1% |
| 13 | EMS S/ABRAZIL HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE | $8.7K | 5 | 0.9% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Olaparib — and from which countries?
Flow of Olaparib exports from India: each country's share and the named importers behind the numbers
Olaparib — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1Russia
Russia emerges as the first largest importing country, achieving a total trade value of $268.5K through 4 shipments. This represents a market share of 29.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Russia has a diverse importer base, with their top importers including:
• JSCRPH - $251.3K (93.6% of country's total business)
Key Insight: Russia demonstrates strong market positioning with an average shipment value of $67.1K, indicating premium pricing strategy compared to the market average of $3.0K.
Russia is a key market for Olaparib imports, representing 29.1% of total trade value.
2Slovenia
Slovenia emerges as the second largest importing country, achieving a total trade value of $161.9K through 50 shipments. This represents a market share of 17.6% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Slovenia has a diverse importer base, with their top importers including:
• LEK PHARMACEUTICALS D.D. - $159.9K (98.8% of country's total business)
Key Insight: Slovenia demonstrates strong market positioning with an average shipment value of $3.2K, indicating premium pricing strategy compared to the market average of $3.0K.
Slovenia is a key market for Olaparib imports, representing 17.6% of total trade value.
3Brazil
Brazil emerges as the third largest importing country, achieving a total trade value of $152.2K through 9 shipments. This represents a market share of 16.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Brazil has a diverse importer base, with their top importers including:
• NAME:- VARGA ROSA PINHEIRO - $13.1K (8.6% of country's total business)
• EMS S/A - $8.7K (5.7% of country's total business)
Key Insight: Brazil demonstrates strong market positioning with an average shipment value of $16.9K, indicating premium pricing strategy compared to the market average of $3.0K.
Brazil is a key market for Olaparib imports, representing 16.5% of total trade value.
4Switzerland
Switzerland emerges as the fourth largest importing country, achieving a total trade value of $78.2K through 13 shipments. This represents a market share of 8.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Switzerland has a diverse importer base, with their top importers including:
• AS PER INVOICE AS - $33.9K (43.4% of country's total business)
• AS PER INVOICE - $15.6K (19.9% of country's total business)
• TO THE EXP CODE E0187FARMACIA INTERNAZIONALE BORDONI SA - $9.8K (12.6% of country's total business)
Key Insight: Switzerland demonstrates strong market positioning with an average shipment value of $6.0K, indicating premium pricing strategy compared to the market average of $3.0K.
Switzerland is a key market for Olaparib imports, representing 8.5% of total trade value.
5Bahamas
Bahamas emerges as the fifth largest importing country, achieving a total trade value of $50.6K through 10 shipments. This represents a market share of 5.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Bahamas has a diverse importer base, with their top importers including:
• AS PER INVOICE ASPER INVOICE - $29.5K (58.2% of country's total business)
• PROGRESSIVE PHARMACEUTICAL DISTRIBU - $13.9K (27.5% of country's total business)
Key Insight: Bahamas demonstrates strong market positioning with an average shipment value of $5.1K, indicating premium pricing strategy compared to the market average of $3.0K.
Bahamas is a key market for Olaparib imports, representing 5.5% of total trade value.
Buyer Segment Analysis
TransData Nexus Olaparib buyer market intelligence
1Buyer Segment Analysis
The importation of Olaparib from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like JSCRPH in Russia and LEK PHARMACEUTICALS D.D. in Slovenia function as intermediaries, procuring Olaparib in bulk to supply to healthcare providers. Their order patterns are characterized by large, regular shipments to maintain a steady supply chain.
- Hospital Groups: Organizations such as LS MEDISUR SAC in Peru likely represent hospital networks that import Olaparib directly for patient treatment. Their purchasing is driven by patient demand and treatment protocols, leading to consistent, moderate-sized orders.
- Retail Chains: Entities like NAME:- VARGA ROSA PINHEIRO in Brazil may be associated with pharmacy chains that import Olaparib to stock their outlets. Their buying behavior is influenced by consumer demand, resulting in variable order sizes and frequencies.
- Re-exporters: Companies such as AS PER INVOICE AS in Switzerland and AS PER INVOICE ASPER INVOICE in the Bahamas might act as re-exporters, importing Olaparib for redistribution to other markets. Their order patterns are opportunistic, based on market demands and trade opportunities.
- Contract Manufacturers: Firms like TO THE IMPORT MANAGER in the United Arab Emirates could be contract manufacturers importing Olaparib as an active pharmaceutical ingredient (API) for formulation into finished products. Their purchasing is typically in large quantities, aligned with production schedules.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Olaparib buyer market intelligence
1Country-Specific Import Regulations
Import regulations for Olaparib vary across the top five importing countries:
- Russia:
- Regulatory Authority: Ministry of Health of the Russian Federation.
- Import Registration Process: Requires submission of a registration dossier, including clinical trial data and quality documentation.
- Estimated Timeline: Approximately 12 to 18 months.
- Import Tariff/Duty: Classified under HS Code 30049099, subject to a standard import duty of 5%.
- Slovenia:
- Regulatory Authority: Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP).
- Import Registration Process: Submission of an application with comprehensive product information and compliance with EU regulations.
- Estimated Timeline: Approximately 12 months.
- Import Tariff/Duty: As an EU member, Slovenia applies a 0% import duty on pharmaceutical products under HS Code 30049099.
- Brazil:
- Regulatory Authority: National Health Surveillance Agency (ANVISA).
- Import Registration Process: Requires a detailed registration dossier, including clinical data and GMP certification.
- Estimated Timeline: Approximately 12 to 24 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to an import duty of 8%.
- Switzerland:
- Regulatory Authority: Swiss Agency for Therapeutic Products (Swissmedic).
- Import Registration Process: Submission of a marketing authorization application, including quality, safety, and efficacy data.
- Estimated Timeline: Approximately 12 to 18 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally exempt from import duties.
- Bahamas:
- Regulatory Authority: Bahamas Pharmacy Council.
- Import Registration Process: Requires submission of product information and compliance with local pharmaceutical regulations.
- Estimated Timeline: Approximately 6 to 12 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to an import duty of 10%.
Navigating these regulatory landscapes is essential for successful market entry and sustained operations in these countries.
Demand Drivers & Market Opportunity
TransData Nexus Olaparib buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Olaparib in importing countries is influenced by several factors:
- Disease Prevalence: Olaparib is primarily used in the treatment of BRCA-mutated cancers, including breast and ovarian cancers. The prevalence of these cancers significantly impacts demand. For instance, in 2025, the World Health Organization (WHO) reported that breast cancer remains the most common cancer globally, with approximately 2.3 million new cases annually.
- Government Healthcare Programs: Many countries have national cancer control programs that prioritize access to effective treatments. Inclusion of Olaparib in these programs can drive demand.
- Universal Health Coverage Expansion: Countries expanding their universal health coverage often include essential cancer treatments, increasing accessibility and demand for drugs like Olaparib.
- WHO Essential Medicines List (EML) Procurement: The WHO's EML guides countries in selecting medicines for public health needs. While Olaparib is not currently listed, its inclusion in national EMLs can enhance procurement and availability.
- Tender-Based Purchasing: Government and institutional tenders for pharmaceuticals can lead to bulk purchasing of Olaparib, influencing market dynamics and demand.
With 99 buyers across 49 countries, the market for Olaparib is diverse. Understanding these demand drivers is crucial for strategic planning and market penetration.
Common Questions — Olaparib Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest olaparib buyer importing from India?
Based on import volume and value, JSCRPH (RUSSIA) leads with $251.3K in imports and a 27.2% market share — the highest of any single olaparib importer. LEK PHARMACEUTICALS D.D. (SLOVENIA) and AS PER INVOICE AS (SWITZERLAND) are the next largest buyers.
QHow many companies buy olaparib from India?
There are 99 active olaparib buyers importing from India, with a combined market of $922.2K across 307 shipments to 49 countries. The top 5 buyers hold 53.8% of total import value, while the remaining 94 buyers handle the other 46.2%.
QWhich countries import the most olaparib from India?
The top importing countries for olaparib from India are Russia (29.1%), Slovenia (17.6%), Brazil (16.5%), Switzerland (8.5%), Bahamas (5.5%). These markets represent the largest demand centres for Indian pharmaceutical exports of olaparib, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for olaparib from India?
The average import transaction value for olaparib from India is $3.0K, with an average unit price of $683.96 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Olaparib buyer market intelligence
1Buyer Segment Analysis
The importation of Olaparib from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like JSCRPH in Russia and LEK PHARMACEUTICALS D.D. in Slovenia function as intermediaries, procuring Olaparib in bulk to supply to healthcare providers. Their order patterns are characterized by large, regular shipments to maintain a steady supply chain.
- Hospital Groups: Organizations such as LS MEDISUR SAC in Peru likely represent hospital networks that import Olaparib directly for patient treatment. Their purchasing is driven by patient demand and treatment protocols, leading to consistent, moderate-sized orders.
- Retail Chains: Entities like NAME:- VARGA ROSA PINHEIRO in Brazil may be associated with pharmacy chains that import Olaparib to stock their outlets. Their buying behavior is influenced by consumer demand, resulting in variable order sizes and frequencies.
- Re-exporters: Companies such as AS PER INVOICE AS in Switzerland and AS PER INVOICE ASPER INVOICE in the Bahamas might act as re-exporters, importing Olaparib for redistribution to other markets. Their order patterns are opportunistic, based on market demands and trade opportunities.
- Contract Manufacturers: Firms like TO THE IMPORT MANAGER in the United Arab Emirates could be contract manufacturers importing Olaparib as an active pharmaceutical ingredient (API) for formulation into finished products. Their purchasing is typically in large quantities, aligned with production schedules.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Olaparib buyer market intelligence
1Country-Specific Import Regulations
Import regulations for Olaparib vary across the top five importing countries:
- Russia:
- Regulatory Authority: Ministry of Health of the Russian Federation.
- Import Registration Process: Requires submission of a registration dossier, including clinical trial data and quality documentation.
- Estimated Timeline: Approximately 12 to 18 months.
- Import Tariff/Duty: Classified under HS Code 30049099, subject to a standard import duty of 5%.
- Slovenia:
- Regulatory Authority: Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP).
- Import Registration Process: Submission of an application with comprehensive product information and compliance with EU regulations.
- Estimated Timeline: Approximately 12 months.
- Import Tariff/Duty: As an EU member, Slovenia applies a 0% import duty on pharmaceutical products under HS Code 30049099.
- Brazil:
- Regulatory Authority: National Health Surveillance Agency (ANVISA).
- Import Registration Process: Requires a detailed registration dossier, including clinical data and GMP certification.
- Estimated Timeline: Approximately 12 to 24 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to an import duty of 8%.
- Switzerland:
- Regulatory Authority: Swiss Agency for Therapeutic Products (Swissmedic).
- Import Registration Process: Submission of a marketing authorization application, including quality, safety, and efficacy data.
- Estimated Timeline: Approximately 12 to 18 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally exempt from import duties.
- Bahamas:
- Regulatory Authority: Bahamas Pharmacy Council.
- Import Registration Process: Requires submission of product information and compliance with local pharmaceutical regulations.
- Estimated Timeline: Approximately 6 to 12 months.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to an import duty of 10%.
Navigating these regulatory landscapes is essential for successful market entry and sustained operations in these countries.
Demand Drivers & Market Opportunity
TransData Nexus Olaparib buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Olaparib in importing countries is influenced by several factors:
- Disease Prevalence: Olaparib is primarily used in the treatment of BRCA-mutated cancers, including breast and ovarian cancers. The prevalence of these cancers significantly impacts demand. For instance, in 2025, the World Health Organization (WHO) reported that breast cancer remains the most common cancer globally, with approximately 2.3 million new cases annually.
- Government Healthcare Programs: Many countries have national cancer control programs that prioritize access to effective treatments. Inclusion of Olaparib in these programs can drive demand.
- Universal Health Coverage Expansion: Countries expanding their universal health coverage often include essential cancer treatments, increasing accessibility and demand for drugs like Olaparib.
- WHO Essential Medicines List (EML) Procurement: The WHO's EML guides countries in selecting medicines for public health needs. While Olaparib is not currently listed, its inclusion in national EMLs can enhance procurement and availability.
- Tender-Based Purchasing: Government and institutional tenders for pharmaceuticals can lead to bulk purchasing of Olaparib, influencing market dynamics and demand.
With 99 buyers across 49 countries, the market for Olaparib is diverse. Understanding these demand drivers is crucial for strategic planning and market penetration.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 99 global importers of Olaparib identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 307 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 49 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
307 Verified Shipments
99 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists